Trinity has acquired Verix, the life sciences commercial intelligence company behind the patented Tovana platform, adding an AI execution layer to TrinityEDGE. Verix’s full team is joining Trinity, and CEO Doron Aspitz will join Trinity’s leadership team while continuing to guide the Tovana roadmap.
Tovana is used by pharmaceutical, biotech, and specialty pharma organizations to turn prescription, claims, clinical, and engagement data into next-best-action recommendations, dynamic targeting, and omnichannel orchestration for brand, field, and digital teams. Trinity plans to progressively integrate the technology into the TrinityEDGE single sign-on environment, with initial joint offerings expected in the first half of 2027.
Trinity said the acquisition addresses a gap between AI-generated insight and commercial execution. Its 2025 Commercial and Medical IT benchmark found that 100% of surveyed organizations had adopted generative AI in some capacity, but innovation confidence averaged only 3 out of 5. A separate benchmark found just 10% of new product planning and commercial strategy leaders had a clear AI strategy they were scaling across workflows.
Verix said Tovana has been developed and validated in pharmaceutical and biotech deployments since 2007. The company cited deployments in oncology and specialty markets, including one large U.S. pharmaceutical oncology division that increased leading KPIs, including new prescriptions, by 15% to 25%. A rare oncology therapy team improved field-facing NPS by 12 times, while a medical device commercial team improved sales outcomes within three months of implementation.
The acquisition also supports Trinity’s broader shift toward combining advisory services with software, data, and AI. Trinity has approximately 1,500 professionals across 14 offices on five continents and has been expanding its TrinityEDGE commercialization platform over the past three years.
KEY QUOTES:
“Every commercial leader I meet is asking how to put AI to work where it actually changes a call, a channel mix, or a forecast. Insight has outpaced execution. Teams are rich in disparate analysis and thin in decisive action in front of a customer. Verix closes that gap. Next-best-action, dynamic targeting, and omnichannel orchestration now sit inside TrinityEDGE, proven in live pharma deployments and backed by 30 years of therapeutic and commercial judgment. That is what it means to lead in integrating human and artificial intelligence for life sciences commercialization.”
Scott Evangelista, Chief Executive Officer Of Trinity
“We built Verix on one conviction: commercial teams deserve intelligence that is timely, explainable, and usable in the flow of work. Joining Trinity is the natural next step. Clients keep the product they rely on and gain the launch, access, and competitive context that tells them whether performance is genuinely competitive. I am proud of what our teams have built and energized by what we can now build together.”
Doron Aspitz, Chief Executive Officer Of Verix
